The Society for Functional Precision Medicine

𝗦𝗙𝗣𝗠 𝗠𝗲𝗺𝗯𝗲𝗿𝘀 – 𝗬𝗼𝘂𝗿 𝗩𝗼𝗶𝗰𝗲 𝗠𝗮𝘁𝘁𝗲𝗿𝘀!
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.

✅ Vote now: sfpm.membershiptoolkit.com

𝗦𝗙𝗣𝗠 𝗠𝗲𝗺𝗯𝗲𝗿𝘀 – 𝗬𝗼𝘂𝗿 𝗩𝗼𝗶𝗰𝗲 𝗠𝗮𝘁𝘁𝗲𝗿𝘀!
Voting is now open for the SFPM Board Member Elections! This is your chance to help shape the future of our organization by selecting the leaders who will represent and guide our mission.

✅ Vote now: sfpm.membershiptoolkit.com

🚨Excited to announce the seminar by Kushtrim Kryeziu, PhD (Oslo University) on "Functional Precision Oncology for Metastatic Colorectal Cancer". Join us TODAY, at 12 PM EDT, open to everyone! Don't miss it and consider joining the SFPM

www.sfpm.io/seminars

What incredible news today. I feel so grateful to have worked closely with Tony over the years and to have witnessed firsthand his vision, energy, and commitment to advancing functional precision medicine. I cannot think of a steadier (and more needed) force at the NCI at this time /n

Please join us in thanking him for his service to SfPM and congratulating him on this momentous new chapter. In light of this transition, new Board openings will be announced, with elections to follow. SfPM members will receive additional details in the coming weeks.

His leadership has strengthened our community and accelerated progress toward a future where functional precision medicine improves outcomes for patients everywhere. We are inspired to see Dr. Letai bring his stabilizing, trailblazing force to the NCI at such a critical time for cancer research.

Dr. Letai has helped advance our field with conviction, generosity, and transformative insight. While we are saddened to see him step away from his role at SfPM, we are profoundly grateful for his years of service and unwavering support of our mission.

Secretary Kennedy Swears in Dr. Anthony Letai as Director of the National Cancer Institute Dr. Letai will serve as NCI’s 18th director.

We want to congratulate our President, Dr. Tony Letai, on his appointment as Director of the NCI. This announcement marks an historic moment for cancer research. Dr. Letai has been a tireless advocate and visionary leader for functional precision medicine 🧵

www.nih.gov/news-events/...

We were honored to host Jens M. Kelm, PhD (PreComb Therapeutics) for our September seminar.

Dr. Kelm shared insights on:
🎯 Dynamic Drug Response Profiling at Scale for Functional Precision Oncology
If you missed the live session, you can now watch it here: www.youtube.com/watch?v=hIkR...

✨ Excited to announce a talk by Jens M. Kelm, PhD (Founder and CSO PreComb Therapeutics AG) on "Dynamic Drug Response Profiling at Scale for Functional Precision Oncology", Join us next Wednesday, September 10, 2025, at 12 PM EDT. Don't miss it!

www.sfpm.io/seminars

Join us this Wednesday 06/11 @ 12:00 PM EST for our monthly SFPM seminar! Dr. Chris Steffi from CompagOs will discuss: "Pioneering Solutions to Understand, Diagnose and Treat Bone Conditions"

More info & link to join: www.sfpm.io/seminars

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

Precision approaches to tackle acquired resistance to cancer, including model-based functional strategies:
www.nature.com/articles/s41...

In panel discussion on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics. Chair Tony Letai. #AACRprecmed25 🧪🧬🖥️

Now: Peter Horak. #AACRprecmed25 🧪🧬🖥️

Now: Keith Ligon. #AACRprecmed25 🧪🧬🖥️

Two of our Board members, Dr. Letai and Dr. Ligon, are part of this #AACRPM25 panel focused on regulatory and non-regulatory challenges to the wide adoption of precision diagnostics

Join us *today* Wednesday 03/12 @ 12:00 PM EST for our monthly SFPM seminar!
Dr. Perova from EMBL-EBI will discuss: "Leveraging CancerModels.Org: enhancing precision oncology through collaborative cancer model resources"

More info: www.sfpm.io/seminars

Now: Keith Flaherty: Targets and therapeutics in need of functional insights to guide drug development in solid tumors #AACRprecmed25 🧪🧬🖥️

Continued 2: KF: Genetic evidence points to multiple resistance pathways #AACRprecmed25 🧪🧬🖥️ https://aacrjournals.org/clincancerres/article/24/24/6195/15360/Landscape-of-EGFR-Dependent-and-Independent

Now: Jeffrey Tyner: Functional omics for novel therapeutic combinations in myeloid malignancies #AACRprecmed25 🧪🧬🖥️

Continued 2: JT: Experimental approach: primary cells -> overnight exposure -> CITE-seq: dynamic changes and cell persistence under therapeutic selective pressure. With @wondermixtape.bsky.social #AACRprecmed25 🧪🧬🖥️

Now: Coleman Lindsley: Dyanmic assessment in leukemia. What is minimal residual disease and does it matter? #AACRprecmed25 🧪🧬🖥️

Now: Sascha Dietrich: Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies #AACRprecmed25 🧪🧬🖥️

AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals Overview for AACR Special Conference in Cancer Research: Functional and Genomic Precision Medicine in Cancer: Different Perspectives, Common Goals

On my way to @theaacr.bsky.social special conference in cancer research: functional and genomic precision medicine in cancer. Who else will be there? @alice.soragnilab.com #AACRprecmed25 www.aacr.org/meeting/aacr...

Elaine Mardis giving introductory remarks

Keith Flaherty starting his lecture

This first AACR meeting on functional and genomic precision medicine has officially started! Dr. Mardis gave the introductory remarks followed by our first plenary speaker, Dr. Flaherty, who will focus on the collision of genomic and functional precision medicine #AACRPM25

Do not miss this great talk tomorrow at 5pm CET (12pm EDT): Zinaida Perova (EMBL) "Leveraging CancerModels.Org: Enhancing Precision Oncology Through Collaborative Cancer Model Resources". @thesfpm.bsky.social

www.sfpm.io/seminars

Join us *today* Wednesday 02/12 @ 12:00 PM EST for our monthly SFPM seminar!

Dr. Andrew Satterlee from UNC will discuss overcoming systemic barriers to functional precision medicine using a versatile ex vivo model of patient brain tumors.

More info: www.sfpm.io/seminars

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial Key PointsBlast-specific ex vivo venetoclax sensitivity correlated strongly with treatment responses and predicted longer survival.VenEx trial showed that

An exciting multicenter phase 2 functional precision medicine clinical trial showing how a rapid ex vivo venetoclax sensitivity assay was the strongest predictor for a favorable treatment response and survival in relapsed/refractory secondary AML

ashpublications.org/blood/articl...

Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy Logun et al. report a unique phase 1 clinical trial design with parallel assessment of patients and rapidly generated patient-derived tumor organoids for CAR-T cell bioactivity in glioblastoma. They showed that cytokine release and the degree of cytolysis in glioblastoma organoids with autologous CAR-T treatment correlated with clinical patient metrics.

Very interesting functional precision medicine study: glioblastoma patient-derived organoids treated with dual-targeting EGFR-IL13Rα2 CAR-Ts mirrored clinical parameters

www.cell.com/cell-stem-ce...

Join us *tomorrow* Wednesday 12/11 @ 12:00 PM EST for our last monthly SFPM seminar of the year!

Drs. Damle and Pillarisetty from @fredhutch.bsky.social will discuss tumor slice cultures as a window into the human TME.

Info to join here: www.sfpm.io/seminars